John Fesko Sells 295 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider John Fesko sold 295 shares of Natera stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $267.99, for a total transaction of $79,057.05. Following the sale, the insider directly owned 183,774 shares in the company, valued at approximately $49,249,594.26. The trade was a 0.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

John Fesko also recently made the following trade(s):

• On Tuesday, July 28th, John Fesko sold 931 shares of Natera stock. The stock was sold at an average price of $254.07, for a total value of $236,539.17.
• On Monday, July 27th, John Fesko sold 782 shares of Natera stock. The stock was sold at an average price of $260.49, for a total value of $203,703.18.
• On Tuesday, May 26th, John Fesko sold 1,438 shares of Natera stock. The shares were sold at an average price of $202.84, for a total value of $291,683.92.

Natera Stock Down 3.4%

NASDAQ:NTRA opened at $265.38 on Friday. Natera, Inc. has a 52 week low of $136.21 and a 52 week high of $288.04. The stock’s fifty day moving average is $252.06 and its two-hundred day moving average is $223.09. The company has a market capitalization of $38.01 billion, a P/E ratio of -162.81 and a beta of 1.51.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. The business had revenue of $752.75 million during the quarter, compared to analysts’ expectations of $661.24 million. Natera had a negative return on equity of 14.74% and a negative net margin of 9.05%.The company’s revenue was up 37.7% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.74) EPS. Sell-side analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Key Headlines Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera reported second-quarter revenue of $752.8 million, up 37.7% year over year and well above analysts’ $661.2 million estimate. Its adjusted loss of $0.47 per share was also slightly better than the $0.49 consensus and improved from a $0.74 loss a year earlier. Gross margin increased to 64.5% from 63.4%. Natera Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The company raised or reaffirmed full-year 2026 revenue guidance at approximately $2.9 billion, ahead of the roughly $2.8 billion analyst consensus. The outlook reinforces expectations for continued demand across Natera’s reproductive health, oncology, and transplant testing businesses.
• Positive Sentiment: Natera submitted its Signatera molecular residual disease test to Japan’s PMDA for approval as a companion diagnostic in muscle-invasive bladder cancer. Regulatory approval could expand Signatera’s international addressable market and create another source of oncology revenue. Natera Submits Signatera to Japan’s PMDA
• Neutral Sentiment: CEO Steven Leonard Chapman, CFO Michael Burkes Brophy, and other executives sold shares totaling about $2.0 million. The transactions were made under pre-arranged Rule 10b5-1 plans to cover tax withholding from vested equity awards, and the executives retained substantial holdings, limiting their value as a negative confidence signal.
• Negative Sentiment: Natera remains unprofitable, reporting a negative net margin and return on equity. Although the quarterly loss narrowed year over year, investors may be focused on the company’s path to sustained earnings, particularly after the stock’s sharp rise and proximity to its 52-week high.

Hedge Funds Weigh In On Natera

Several hedge funds have recently bought and sold shares of NTRA. Abbot Financial Management Inc. acquired a new position in Natera in the 2nd quarter valued at about $1,537,000. Flputnam Investment Management Co. purchased a new stake in Natera during the second quarter worth about $253,000. Global Retirement Partners LLC acquired a new stake in shares of Natera during the second quarter worth about $1,530,000. Bank of New York Mellon Corp acquired a new stake in shares of Natera during the second quarter worth about $149,278,000. Finally, Leeward Financial Partners LLC purchased a new position in shares of Natera in the second quarter valued at approximately $5,308,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on NTRA. Wall Street Zen lowered shares of Natera from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Robert W. Baird set a $265.00 price target on shares of Natera in a research note on Friday, May 8th. Piper Sandler restated an “overweight” rating and issued a $249.00 price objective on shares of Natera in a report on Tuesday, May 12th. TD Cowen reaffirmed a “buy” rating on shares of Natera in a research report on Wednesday, July 15th. Finally, BTIG Research set a $275.00 target price on shares of Natera and gave the company a “buy” rating in a report on Wednesday, June 24th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $267.83.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.